Hamlet BioPharma Valuation
Is HAMLET B undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of HAMLET B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate HAMLET B's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate HAMLET B's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for HAMLET B?
Other financial metrics that can be useful for relative valuation.
| What is HAMLET B's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | SEK 612.33m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 19660.1x |
| Enterprise Value/EBITDA | -17.9x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does HAMLET B's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 4.5x | ||
FLUO FluoGuide | 8.3x | 49.9% | SEK 474.3m |
ONCO Oncopeptides | 2.3x | 39.3% | SEK 450.8m |
ISOFOL Isofol Medical | 5.5x | n/a | SEK 592.8m |
MVIR Medivir | 1.8x | 35.0% | SEK 324.2m |
HAMLET B Hamlet BioPharma | 9.4x | n/a | SEK 612.3m |
Price-To-Book vs Peers: HAMLET B is expensive based on its Price-To-Book Ratio (9.4x) compared to the peer average (4.5x).
Price to Earnings Ratio vs Industry
How does HAMLET B's PE Ratio compare vs other companies in the SE Biotechs Industry?
Price-To-Book vs Industry: HAMLET B is expensive based on its Price-To-Book Ratio (9.4x) compared to the Swedish Biotechs industry average (2.8x).
Price to Book Ratio vs Fair Ratio
What is HAMLET B's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 9.4x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate HAMLET B's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.